Generalized myasthenia gravis is an autoimmune muscular disorder that can cause muscle weakness, difficulty breathing and altered vision, among other symptoms. The Myasthenia Gravis Foundation of America said a 2021 study estimated that 37 out of every 100,000 people in the U.S. have myasthenia gravis.
Livsayis, also known as cemdisiran, is a small interfering RNA therapeutic. Regeneron said it lowers circulating levels of C5 protein, limiting terminal complement activation, which the company described as a key driver of the disease.
According to Regeneron, Livsayis is the first and only approved siRNA therapy for generalized myasthenia gravis. The company also said it is the only FDA-approved treatment for the condition administered subcutaneously four times a year.





Comments (0)
No comments yet. Be the first!